

January 2, 2024
Web Announcement 3251

Drug Use Review (DUR) Board Approves Changes Effective January 2, 2024

The Nevada Medicaid Drug Use Review (DUR) Board met on July 27, 2023 and voted to adopt the following changes effective January 2, 2024:

Drug Class/Program	Changes
Strensiq® (asfotase alfa)	Addition of new clinical criteria
Gonadotropin Releasing Hormone Receptor (GnRH) Antagonist and Combinations	Addition of new clinical criteria for Myfembree® (relugolix/estradiol/norethindrone acetate)
Tziel® (teplizumab-mzvv)	Addition of new clinical criteria
Immunomodulator Drugs	Updates to clinical criteria for infliximab biosimilars

Prior Authorization forms may be found on the below webpages:
<https://nevadamedicaid.magellanrx.com/provider/forms> (pharmacy/point-of-sale)